These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 25350320

  • 1. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.
    Pae CU, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Serretti A.
    J Psychiatry Neurosci; 2015 May; 40(3):174-86. PubMed ID: 25350320
    [Abstract] [Full Text] [Related]

  • 2. Vortioxetine for depression in adults.
    Koesters M, Ostuzzi G, Guaiana G, Breilmann J, Barbui C.
    Cochrane Database Syst Rev; 2017 Jul 05; 7(7):CD011520. PubMed ID: 28677828
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Li G, Wang X, Ma D.
    Clin Drug Investig; 2016 Jul 05; 36(7):509-17. PubMed ID: 27067232
    [Abstract] [Full Text] [Related]

  • 5. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME.
    Int J Neuropsychopharmacol; 2013 Mar 05; 16(2):313-21. PubMed ID: 22963932
    [Abstract] [Full Text] [Related]

  • 6. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults.
    Thase ME, Mahableshwarkar AR, Dragheim M, Loft H, Vieta E.
    Eur Neuropsychopharmacol; 2016 Jun 05; 26(6):979-93. PubMed ID: 27139079
    [Abstract] [Full Text] [Related]

  • 7. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
    Montgomery SA, Nielsen RZ, Poulsen LH, Häggström L.
    Hum Psychopharmacol; 2014 Sep 05; 29(5):470-82. PubMed ID: 25087600
    [Abstract] [Full Text] [Related]

  • 8. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.
    Mahableshwarkar AR, Jacobsen PL, Chen Y, Serenko M, Trivedi MH.
    Psychopharmacology (Berl); 2015 Jun 05; 232(12):2061-70. PubMed ID: 25575488
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR, Jacobsen PL, Chen Y.
    Curr Med Res Opin; 2013 Mar 05; 29(3):217-26. PubMed ID: 23252878
    [Abstract] [Full Text] [Related]

  • 12. The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis.
    Fu J, Chen Y.
    Psychopharmacology (Berl); 2015 Jan 05; 232(1):7-16. PubMed ID: 24871704
    [Abstract] [Full Text] [Related]

  • 13. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis.
    Meeker AS, Herink MC, Haxby DG, Hartung DM.
    Syst Rev; 2015 Mar 01; 4():21. PubMed ID: 25874839
    [Abstract] [Full Text] [Related]

  • 14. Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.
    Llorca PM, Lançon C, Brignone M, Rive B, Salah S, Ereshefsky L, Francois C.
    Curr Med Res Opin; 2014 Dec 01; 30(12):2589-606. PubMed ID: 25249164
    [Abstract] [Full Text] [Related]

  • 15. Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials.
    Maneeton N, Maneeton B, Srisurapanont M, Martin SD.
    BMC Psychiatry; 2012 Sep 27; 12():160. PubMed ID: 23017200
    [Abstract] [Full Text] [Related]

  • 16. Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis.
    Pae CU, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Serretti A.
    J Psychiatr Res; 2015 May 27; 64():88-98. PubMed ID: 25851751
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.
    Boulenger JP, Loft H, Olsen CK.
    Int Clin Psychopharmacol; 2014 May 27; 29(3):138-49. PubMed ID: 24257717
    [Abstract] [Full Text] [Related]

  • 18. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
    Wang G, Gislum M, Filippov G, Montgomery S.
    Curr Med Res Opin; 2015 Apr 27; 31(4):785-94. PubMed ID: 25650503
    [Abstract] [Full Text] [Related]

  • 19. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.
    Jacobsen PL, Mahableshwarkar AR, Serenko M, Chan S, Trivedi MH.
    J Clin Psychiatry; 2015 May 27; 76(5):575-82. PubMed ID: 26035185
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis.
    He H, Wang W, Lyu J, Zheng J, Guo L, An X, Fan Y, Ma X.
    J Psychiatr Res; 2018 Jan 27; 96():247-259. PubMed ID: 29127931
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.